Friday, November 20, 2015

ABT-122 at the ACR 2015 Meeting in San Francisco


There has been one publication on ABT-122 at the ACR 2015 Annual Meeting in San Francisco. ABT-122 is an anti-TNF/IL-17 Dual Variable Domain immunoglobulin (DVD-Ig™). It had been "demonstrated that dual neutralization of TNF and IL-17 provides greater efficacy than blocking either cytokine alone in mouse collagen induced arthritis". But we already know, that for instance secukinumab (an anti-IL-17a MAB) did not achieve the primary endpoint (ACR20) in patients with rheumatoid arthritis. So, from the beginning I’m very sceptical. But let’s look at the study.

Roy Fleischmann and colleagues presented: “Safety, Tolerability, and Pharmacodynamics of ABT-122, a Dual TNF- and IL-17-Targeted Dual Variable Domain (DVD)-IgTM in Subjects with Rheumatoid Arthritis”. Background/Purpose: […] ABT-122 is […] is hypothesized to provide greater clinical responses in patients with RA.” Conclusion: “ABT-122 demonstrated a well tolerated safety profile in subjects with RA through 8 weeks of dosing up to 3 mg/kg, […] decreases in these chemokines [CXCL9, CXCL10, and CCL23] indicate that ABT-122 rapidly modulates potential pathophysiologic pathways in RA patients, with evidence for persistent effects after cessation of dosing. These results suggest that dual neutralization of TNF and IL-17 may provide an opportunity to control inflammation and its clinical manifestations in RA subjects and in other immune-mediated inflammatory diseases.” Thin ice!

I think the first step in convincing me would be testing ABT-122 against a TNF-inhibitor. As ABT-122 comes from AbbVie, testing against Humira shouldn’t be a problem. Until then, IL-17 in ABT-122 may be nothing more than a pinch of cinnamon in the coffee, which changes the flavour but not the caffeine content.

References:
Fleischmann R, Wagner F, Kivitz AJ, Mansikka HT, Khan N, Liu J, Gagnon J, Hong F, Ruzek M, Padley RJ. Safety, Tolerability, and Pharmacodynamics of ABT-122, a Dual TNF- and IL-17-Targeted Dual Variable Domain (DVD)-IgTM in Subjects with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). http://acrabstracts.org/abstract/safety-tolerability-and-pharmacodynamics-of-abt-122-a-dual-tnf-and-il-17-targeted-dual-variable-domain-dvd-igtm-in-subjects-with-rheumatoid-arthritis/. Accessed November 20, 2015.


Thursday, November 19, 2015

Brodalumab at the ACR 2015 Meeting in San Francisco


There has been one publication on brodalumab at the ACR 2015 Annual Meeting in San Francisco.
Brodalumab is an anti-IL 17 receptor MAB, which is a promising new drug on the horizon against psoriatic arthritis as it targets IL-17, which plays a role "in the pathogenesis and ongoing inflammation of psoriatic disease". But only one study!

Mark C. Genovese and colleagues presented: “Two-Year Clinical Response to Brodalumab, an Anti-Interleukin-17 Receptor Antibody, in Patients with Psoriatic Arthritis”. Conclusion: “Treatment with brodalumab resulted in a safety profile comparable to the overall safety profile of biologics approved for PsA [psoriatic arthritis] and meaningful clinical benefit that was maintained through week 108 in patients with PsA in this ongoing OLE [open label extension].”

An evaluation of clinical data of phase 2 study isn’t very convincing. Where’s data on radiographic progression after two years? The sponsor doesn’t seem to push the agenda. Still committed or simply keeping it up at low level in case something weird happens to Secukinumab to push it from getting approval as a drug. Else I don’t see a reason, why not recruiting for a phase 3 study.

References:
Genovese MC, Mease PJ, Greenwald M, Ritchlin CT, Beaulieu A, Deodhar AA, Newmark R, Feng J, Erondu N, Nirula A. Two-Year Clinical Response to Brodalumab, an Anti-Interleukin-17 Receptor Antibody, in Patients with Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). http://acrabstracts.org/abstract/two-year-clinical-response-to-brodalumab-an-anti-interleukin-17-receptor-antibody-in-patients-with-psoriatic-arthritis/. Accessed November 19, 2015.


Sirukumab at the ACR 2015 Meeting in San Francisco


There has been one publication on sirukumab at the ACR 2015 Annual Meeting in San Francisco. Sirukumab is a human MAB that binds to IL-6, designed for the treatment of rheumatoid arthritis. So sirukumab will compete with tocilizumab. I’ve seen the first studies at the EULAR 2012 Meeting in Berlin. So now we have one study. You know, how suspicious I am, and this makes me even more suspicious.

Tsutomu Takeuchi and colleagues presented: “One-Year Safety of Sirukumab Monotherapy: Results from a Randomized, Double-Blind, Parallel-Group, Multicenter Study in Japanese Subjects with Moderate to Severe Rheumatoid Arthritis”. It’s a phase 2 study. Conclusions: “Sirukumab 50mg q4 and 100mg q2 monotherapy dose regimens for 52 weeks were well tolerated in Japanese RA patients. […] The proportions of ACR 20/50/70 responses at Week 24 in the 100mg q2 group were numerically higher than those in the 50mg q4 group; however, the number of subjects was too limited to make conclusions about dose response.”

Why is the sponsor not pushing to get to the market? If he wants to take part of the IL-6 piece of the cake, he should hurry as the cake is cut into more and more pieces. I see a lack of commitment. And actually I don’t see a medical reason to have another IL-6 inhibitor.

References:
Takeuchi T, Yamanaka H, Harigai M, Tamamura R, Kato Y, Ukyo Y, Nakano T, Ota T, Hsu B, Tanaka Y. One-Year Safety of Sirukumab Monotherapy: Results from a Randomized, Double-Blind, Parallel-Group, Multicenter Study in Japanese Subjects with Moderate to Severe Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). http://acrabstracts.org/abstract/one-year-safety-of-sirukumab-monotherapy-results-from-a-randomized-double-blind-parallel-group-multicenter-study-in-japanese-subjects-with-moderate-to-severe-rheumatoid-arthritis/. Accessed November 19, 2015.


Carpe Diem Haiku Writing Techniques No. 19 as is above as below


Let go of your grip
The wind blows without torture
Leaves falling to ground

The sycamore leaves
Sailing down and marching
To oblivion

Looking at Li Bo (李伯)
And centuries don’t matter
Drinking with the moon



Carpe Diem Haiku No. 861 Sacred Stones


Three times around
Searched by security men
Then the engine's roar




All the Sacred Stones
Don't hide their secrets from you
Power lies in you

From every journey
You take some stones back to home
Just for memories




Tregalizumab at the ACR 2015 Meeting in San Francisco


There has been one publication on tregalizumab at the ACR 2015 Annual Meeting in San Francisco. “Tregalizumab (BT-061) is a humanized, anti-CD4 mAb, inducing selective Treg activation in vitro.” It seems an interesting concept, as the authors of the study point out: “Previous trials suggested efficacy in RA at doses ≥25 mg subcutaneously (SC).” But let’s come to the dismal truths of the study.

Ronald F. van Vollenhoven and colleagues presented: “A Phase 2b Study Evaluating the Efficacy and Safety of Subcutaneously Administered Tregalizumab in Subjects with Active Rheumatoid Arthritis (RA) Despite Treatment with Methotrexate (MTX)”. But they had to conclude: “No tested doses of tregalizumab demonstrated significant efficacy improving signs and symptoms of active RA based on ACR20 responses at wk 12 and 24 despite dose dependent down-modulation of CD4 expression. Tregalizumab was generally well tolerated.”

Does this mean, that tregalizumab should be abandoned? I guess not. Maybe Tregs act differently in vivo. And I guess, the team around Ronald F. van Vollenhoven will come out with a new idea, on how to make the concept work. Maybe it only works in a form of combination. Looking forward to new developments with tregalizumab.

References:
van Vollenhoven RF, Keystone EC, Strand V, Pacheco-Tena C, Vencovsky J, Behrens F, Zipp D, Rharbaoui F, Wolter R, Tiemann RD, Knierim L, Schmeidl R, Zhou X, Aigner S, Daelken B, Wartenberg-Demand A. A Phase 2b Study Evaluating the Efficacy and Safety of Subcutaneously Administered Tregalizumab in Subjects with Active Rheumatoid Arthritis (RA) Despite Treatment with Methotrexate (MTX) [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). http://acrabstracts.org/abstract/a-phase-2b-study-evaluating-the-efficacy-and-safety-of-subcutaneously-administered-tregalizumab-in-subjects-with-active-rheumatoid-arthritis-ra-despite-treatment-with-methotrexate-mtx/. Accessed November 19, 2015.


Iguratimod at the ACR 2015 Meeting in San Francisco


There has been one publication on iguratimod at the ACR 2015 Annual Meeting in San Francisco. Iguratimod is a novel disease modifying anti-rheumatic drug (DMARD); chemical formula: N-(3-Formamido-4-oxo-6-phenoxy-4H-chromen-7-yl)-methanesulfonamide. Iguratimod is characterized by inhibitory effects on immunoglobulin production in B cells as well as inhibiting cytokine production. Its' mode of action comes by suppression of nuclear factor kappa B (NF-kB) activation. As I have already written on Iguratimod before, please look for the links below. 2012 there had been three studies, 2013 one study at the EULAR Meeting in Madrid (a study by a Chinese group), only one study at the ACR 2013 Meeting, but three studies at the EULAR 2014 meeting in Paris, also three studies at the ACR 2014 Meeting and the 2015 EULAR Meeting in Rome. But let’s look at the study now.

Tsuneo Kondo and colleagues presented: “Clinical and Radiographic Outcome of Iguratimod for Rheumatoid Arthritis”. Results: “[…] DAS28-ESR and SDAI decreased significantly from 4.49±1.33 to 3.12±1.08 and from 18.5±10.9 to 8.3±6.34 in 52 weeks respectively (P < 0.01). Remission and LDA rate in DAS28-ESR were 29.0% and 24.2%. HAQ-DI score also decreased from 1.2±0.8 to 0.85±0.79. The percentage of patients with no radiographic progression (ΔmTSS < 0.5) was 56.8%, while that of rapid radiographic progression (ΔTSS > 5) was 13.5%. The mean estimated yearly progression was 9.9 ± 15.6 at baseline. After 52 weeks of IGU treatment, the mean change was significantly reduced to 1.2 ± 2.5(P < 0.01). […]”. So, the author’s concluded: „IGU reduced disease activity and radiographic progression with RA patients. IGU is generally safe and tolerable and may have a good cost effectiveness. So iguratimod be a new useful option as small molecule DMARDs.

Iguratimod has shown to be a promising candidate for treatment of active rheumatoid arthritis and might become a needed alternative in the conventional (traditional) DMARD class. Iguratimod is approved in Japan and hopefully it will be approved in the rest of the world soon. We now have data on radiographic progression, so the drug is one step nearer to approval. But iguratimod is making progress in to little and too few steps. The sponsor of studies should more committed.

References:
Kondo T, Shibata A, Sakai R, Kikuchi J, Chino K, Okuyama A, Takei H, Amano K. Clinical and Radiographic Outcome of Iguratimod for Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). http://acrabstracts.org/abstract/clinical-and-radiographic-outcome-of-iguratimod-for-rheumatoid-arthritis/. Accessed November 18, 2015.

Links:
Iguratimod at the EULAR Meeting 2012

Iguratimod at the EULAR Meeting 2013

Iguratimod at the ACR 2013 Meeting

Iguratimod at the EULAR 2014 Meeting